MAPT and Alzheimer disease: As the full length IDR is too long to characterize by this methodology, we have followed the “divide and conquer” approach implemented by Zweckstetter et al. to characterize tau, a similarly sized IDP implicated in Alzheimer’s disease and other tauopathies [30].